Joel Beatty
Stock Analyst at Baird
(4.51)
# 266
Out of 5,090 analysts
201
Total ratings
48.77%
Success rate
29.41%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $11.17 | +25.34% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $166.39 | +25.61% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $81.62 | +53.15% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $14.45 | +31.49% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.68 | +90.48% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $44.90 | +49.24% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.44 | +145.90% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $39.36 | -77.13% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $26.59 | +16.61% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $21.04 | +14.07% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $916.31 | -25.79% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $20.30 | +42.86% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $77.83 | -15.19% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $148.41 | +9.16% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $29.30 | +39.96% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $12.48 | +28.26% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $191.83 | -61.95% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $23.14 | +38.32% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $72.73 | +3.12% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.77 | +295.48% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $53.82 | +20.78% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $36.60 | +96.72% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.54 | +15,484.42% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.26 | +256.18% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $18.00 | +38.89% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $19.75 | +41.81% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.89 | +748.81% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.93 | -35.23% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.30 | +3,284.62% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $64.67 | -10.31% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $35.95 | -33.24% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $6.78 | +165.49% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.16 | +177.78% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $6.87 | +307.87% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $464.56 | -62.33% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $5.23 | +167.94% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $22.81 | +373.48% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $81.64 | -4.46% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $13.09 | +663.94% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.48 | +628.16% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.79 | +11,789.04% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.81 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.84 | +119.46% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $3.03 | +39,451.75% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $12.02 | +58.07% | 3 | Nov 10, 2017 |
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $11.17
Upside: +25.34%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $166.39
Upside: +25.61%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $81.62
Upside: +53.15%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $14.45
Upside: +31.49%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.68
Upside: +90.48%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $44.90
Upside: +49.24%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.44
Upside: +145.90%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $39.36
Upside: -77.13%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $26.59
Upside: +16.61%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $21.04
Upside: +14.07%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $916.31
Upside: -25.79%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $20.30
Upside: +42.86%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $77.83
Upside: -15.19%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $148.41
Upside: +9.16%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $29.30
Upside: +39.96%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $12.48
Upside: +28.26%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $191.83
Upside: -61.95%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $23.14
Upside: +38.32%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $72.73
Upside: +3.12%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.77
Upside: +295.48%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $53.82
Upside: +20.78%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $36.60
Upside: +96.72%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.54
Upside: +15,484.42%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.26
Upside: +256.18%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $18.00
Upside: +38.89%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $19.75
Upside: +41.81%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.89
Upside: +748.81%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.93
Upside: -35.23%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.30
Upside: +3,284.62%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $64.67
Upside: -10.31%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $35.95
Upside: -33.24%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $6.78
Upside: +165.49%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.16
Upside: +177.78%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $6.87
Upside: +307.87%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $464.56
Upside: -62.33%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $5.23
Upside: +167.94%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $22.81
Upside: +373.48%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $81.64
Upside: -4.46%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $13.09
Upside: +663.94%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.48
Upside: +628.16%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.79
Upside: +11,789.04%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.81
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.84
Upside: +119.46%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $3.03
Upside: +39,451.75%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $12.02
Upside: +58.07%